NEW YORK, July 12, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Neurotrope, Inc. (“Neurotrope”) (NASDAQ:NTRP) between January 7, 2016, and April 28, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Hinshaw v. Neurotrope, Inc., et al. (Case No. 1:17-cv-03718) in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/neurotrope-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Take Action: if you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



